Download PDF
Aktuelle Urol 2012; 43(3): 157-161
DOI: 10.1055/s-0031-1284035
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Chemoprävention des Prostatakarzinoms – Ein Plädoyer

Chemoprevention of Prostate Cancer – A Plea
B. J. Schmitz-Dräger
1   Urologie, EuromedClinic, Fürth
,
E. Bismarck
1   Urologie, EuromedClinic, Fürth
,
O. Schöffski
2   Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg
,
C. Fischer
3   Urologische Klinik, Klinikum Hohe Warte, Bayreuth
› Author Affiliations
Further Information

Publication History

Publication Date:
25 May 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Eine hohe Prävalenz, das bevorzugte Auftreten in höherem Alter, eine häufig langsame Progression und hohe Behandlungskosten machen die Diagnostik und Therapie des Prostatakarzinoms zu einer besonderen Herausforderung. Eine wirksame Prävention könnte etliche der genannten Probleme bessern. Zwei randomisierte, kontrollierte Studien belegen, dass eine wirksame Chemoprävention des Prostatakarzinoms mit einem 5α-Reduktase Hemmer (Finasterid, Dutasterid) tatsächlich möglich ist. Daneben existieren auch Evidenzen für weitere Substanzen aus der Gruppe der selektiven Östrogenrezeptor Modulatoren (SERMs), NSAIDs und Statine. Die vorliegende Übersicht untersucht die Risiken und Vorteile einer Chemoprävention nicht zuletzt auch unter gesundheitsökonomischen Aspekten. Die Autoren kommen zu dem Schluss, dass die Optionen einer Chemoprävention ergebnisoffen geprüft werden sollten.

Abstract

The high disease prevalence, the presentation in older age, a frequently slowly progressing course of disease, and high costs make the diagnosis of and therapy for prostate cancer a special challenge for urologists. Effective prevention of the disease may help to improve some of the problems mentioned above. Two randomised, controlled studies have proved that effective chemoprevention of prostate cancer is viable using 5α−reductase inhibitors (finasteride, dutasteride). Furthermore, there is increasing evidence that other compounds, e. g., selective oestrogen receptor modulators (SERMs), NSAIDs and statins might also be effective. This review investigates potential risks and benefits of chemoprevention including a consideration of health economical aspects. The authors conclude that the options of chemoprevention should be investigated in an open and unbiased way.

Schlüsselwörter

Chemoprävention - Prostatakarzinom - 5α-Reduktasehemmer

Key words

chemoprevention - prostate cancer - 5α-reductase inhibitor
 

  • Literatur

  • 1 Schmitz-Dräger BJ, Lümmen G, Bismarck E. Mitglieder des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK) et al. Prävention Urologischer Erkrankungen. Urologe A 2012;
    PubMedGoogle Scholar
  • 2 Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224
    CrossrefPubMedGoogle Scholar
  • 3 Scardino P. The prevention of prostate cancer – the dilemma continues. N Engl J Med 2003; 349: 297-299
    CrossrefPubMedGoogle Scholar
  • 4 Teillac P, Abrahamsson PA. The prostate cancer prevention trial and its implications for clinical practise: a European consensus. Eur Urol Suppl 2006; 5: 640-646
    CrossrefPubMedGoogle Scholar
  • 5 Sarvis JA, Thompson IM. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep 2008; 10 (06) 529-532
    CrossrefPubMedGoogle Scholar
  • 6 Andriole GL, Bostwick DG, Brawley OW. REDUCE Study Group et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13) 1192-1202
    CrossrefPubMedGoogle Scholar
  • 7 Wilt TJ, Macdonald R, Hagerty K et al. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int 2010; 106 (10) 1444-1451
    CrossrefPubMedGoogle Scholar
  • 8 Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. 5-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev; 2008 (2). CD007091
    PubMedGoogle Scholar
  • 9 Roberts EG, Vona-Davis L, Riggs DR et al. COX-2 inhibition and cancer: experimental findings and clinical correlates. W V Med J 2004; 100: 96-100
    PubMedGoogle Scholar
  • 10 Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 2009; 3 (04) 323-330
    PubMedGoogle Scholar
  • 11 Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127 (07) 1680-1691
    CrossrefPubMedGoogle Scholar
  • 12 van Adelsberg J, Gann P, Ko AT et al. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 2007; 23: 2063-2070
    CrossrefPubMedGoogle Scholar
  • 13 Price D, Stein B, Goluboff E et al. Toremifene for the prevention of prostate cancer among 514 men with high-grade prostatic intraepithelial neoplasia (PIN): results of a double-blind, placebo-controlled phase II B trial. J Urol 2006; 176: 965-970
    CrossrefPubMedGoogle Scholar
  • 14 Moyad MA. Why a statin and / or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. Urol Oncol 2004; 22: 466-471
    CrossrefPubMedGoogle Scholar
  • 15 Moyad MA. Why a statin and / or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Urol Oncol 2004; 22: 472-477
    CrossrefPubMedGoogle Scholar
  • 16 Hsieh LJ, Carter HB, Landis PK et al. Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 2003; 61: 297-301
    CrossrefPubMedGoogle Scholar
  • 17 Strom SS, Wang X, Pettaway CA et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 2005; 11: 6889-6894
    CrossrefPubMedGoogle Scholar
  • 18 Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904
    CrossrefPubMedGoogle Scholar
  • 19 Farwell WR, Scranton RE, Lawler EV et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008; 100: 134-139
    CrossrefPubMedGoogle Scholar
  • 20 Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 2008; 17: 259-268
    CrossrefPubMedGoogle Scholar
  • 21 Malik A, Afaq F, Sarfaraz S et al. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A 2005; 102: 14813-14818
    CrossrefPubMedGoogle Scholar
  • 22 Unger JM, Thompson Jr IM, LeBlanc M et al. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer 2005; 103: 1375-1380
    CrossrefPubMedGoogle Scholar
  • 23 Moinpour CM, Darke AK, Donaldson GW et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1025-1035
    CrossrefPubMedGoogle Scholar
  • 24 Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ. Guidelines on the Management of Non-neurogenic Male LUTS. EAU Guidelines; 2011
    PubMedGoogle Scholar
  • 25 Loeb S, Vonesh EF, Metter EJ et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?. J Clin Oncol 2011; 29: 464-467
    PubMedGoogle Scholar
  • 26 Berger JS, Roncaglioni MC, Avanzini F et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313
    CrossrefPubMedGoogle Scholar
  • 27 Ridker PM, MacFadyen JG, Fonseca FA. JUPITER Study Group et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009; 2 (06) 616-623
    CrossrefPubMedGoogle Scholar
  • 28 Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, Schmid H-P, van der Kwast TH, Wiegel T, Zattoni F. Guidelines on prostate cancer. EAU Guidelines; 2011
    PubMedGoogle Scholar
  • 29 Wirth M, Weißbach L, Albrecht C, Göckel-Beining B, Fröhner M, Hinkelbein W, Miller K, Rübben H, Stöckle M, Wenz F, Wiegel T, Wolff J, Wörmann B. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. 2011 Version 2.0, Aktualisierung 2011
    PubMedGoogle Scholar